Abstract
The criteria for treatment refractoriness for the use of clozapine are necessarily set at a high level because of the potential risk of agranulocytosis with this treatment. However, a more liberal definition should be considered to better appreciate the limitations of current therapies and prepare for switching to the next generation of clozapine-like drugs that do not cause agranulocytosis. It is suggested that failure of therapy to bring about the best premorbid level of functioning be considered as a starting point for treatment-resistance.
Original language | English (US) |
---|---|
Pages (from-to) | 563-565 |
Number of pages | 3 |
Journal | Schizophrenia bulletin |
Volume | 16 |
Issue number | 4 |
DOIs |
|
State | Published - 1990 |
ASJC Scopus subject areas
- Psychiatry and Mental health